Abstract
Sphingosine kinase (SK) 1 and 2 are lipid kinases that phosphorylate sphingosine to form sphingosine-1 phosphate, a potent signalling molecule with pleiotrophic effects. SK1 is commonly up-regulated in tumours and its inhibition or genetic ablation has been shown to slow tumour growth as well as sensitise cancer cells to other chemotherapeutics. Therefore, SK1 is of particular interest as a target therapeutic intervention in cancer. Initial SK inhibitors were sphingosine derivatives and displayed efficacy in a number of disease models, establishing a premise for SK inhibition for anti-proliferative and anti-inflammatory therapies, even though these compounds had questionable specificity. More recently, a number of new SK inhibitors have been developed that display higher affinities and greater specificity for the SKs. Here we summarise the current small molecule inhibitors and related approaches for targeting the SKs, and their in vitro and in vivo efficacy. Furthermore, we highlight findings demonstrating the success of SK inhibition in cancer and a range of other disease models that promotes the continued interest in targeting the SKs for therapeutic benefit.
Keywords: Sphingosine kinase, sphingosine 1-phosphate, inhibitor, sphingosine, lipid kinase, cancer therapy
Current Cancer Drug Targets
Title: Inhibitors of the Sphingosine Kinase Pathway as Potential Therapeutics
Volume: 10 Issue: 4
Author(s): M.R. Pitman and S.M. Pitson
Affiliation:
Keywords: Sphingosine kinase, sphingosine 1-phosphate, inhibitor, sphingosine, lipid kinase, cancer therapy
Abstract: Sphingosine kinase (SK) 1 and 2 are lipid kinases that phosphorylate sphingosine to form sphingosine-1 phosphate, a potent signalling molecule with pleiotrophic effects. SK1 is commonly up-regulated in tumours and its inhibition or genetic ablation has been shown to slow tumour growth as well as sensitise cancer cells to other chemotherapeutics. Therefore, SK1 is of particular interest as a target therapeutic intervention in cancer. Initial SK inhibitors were sphingosine derivatives and displayed efficacy in a number of disease models, establishing a premise for SK inhibition for anti-proliferative and anti-inflammatory therapies, even though these compounds had questionable specificity. More recently, a number of new SK inhibitors have been developed that display higher affinities and greater specificity for the SKs. Here we summarise the current small molecule inhibitors and related approaches for targeting the SKs, and their in vitro and in vivo efficacy. Furthermore, we highlight findings demonstrating the success of SK inhibition in cancer and a range of other disease models that promotes the continued interest in targeting the SKs for therapeutic benefit.
Export Options
About this article
Cite this article as:
Pitman M.R. and Pitson S.M., Inhibitors of the Sphingosine Kinase Pathway as Potential Therapeutics, Current Cancer Drug Targets 2010; 10 (4) . https://dx.doi.org/10.2174/156800910791208599
DOI https://dx.doi.org/10.2174/156800910791208599 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Circulating Biomarkers Determining Inflammation in Atherosclerosis Progression
Current Medicinal Chemistry Current Drug Nano-targeting Strategies for Improvement in the Diagnosis and Treatment of Prevalent Pathologies such as Cardiovascular and Renal Diseases
Current Drug Targets Prevention of Macrovascular Disease in Type 2 Diabetic Patients: Blockade of the Renin-Angiotensin-Aldosterone System
Current Diabetes Reviews Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Non-Steroidal Anti-Inflammatory Drugs used as a Treatment Modality in Subarachnoid Hemorrhage
Current Drug Safety Lipoproteins, Stroke and Statins
Current Vascular Pharmacology Chemokines in Cardiovascular Remodeling: Clinical and Therapeutic Implications
Current Molecular Medicine Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry Bioenergetics and Mitochondrial Dysfunction in Aging: Recent Insights for a Therapeutical Approach
Current Pharmaceutical Design The Role of Platelets in Athero-Thrombotic Events
Current Pharmaceutical Design Recent Development of Hydrogen Sulfide Therapeutics in the Treatment of Cardiovascular Diseases
Current Topics in Medicinal Chemistry Relations of Magnesium Intake with Metabolic Risk Factors and Risks of Type 2 Diabetes, Hypertension, and Cardiovascular Disease: A Critical Appraisal
Current Nutrition & Food Science Emerging Roles of microRNAs in the Molecular Responses to Hypoxia
Current Pharmaceutical Design Blood Pressure Management in Metabolic Syndrome
Current Hypertension Reviews Synthesis and Biological Activity of the Pyridine-hexacyclic-steroid Derivative on a Heart Failure Model
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Effect of Aging On Angiogenesis and Arteriogenesis
Current Cardiology Reviews Effect of SDF-1 α on Endogenous Mobilized and Transplanted Stem Cells in Regeneration after Myocardial Infarction
Current Pharmaceutical Design The Long Way to Objectify Organ Damage Related to Cocaine Abuse: Oxidative Stress is the Main Culprit
Mini-Reviews in Organic Chemistry The Role of Transforming Growth Factor-β in Cardiac Fibrosis
Current Enzyme Inhibition Unusual Clinical Manifestations of the Antiphospholipid Syndrome
Current Rheumatology Reviews